Terremoto Therapeutics has raised $108 million to advance its pipeline of drugs designed to target the AKT protein, a key signaling molecule implicated in cancer growth. The California-based biotech plans to use the capital to push its lead candidate through clinical development and bring a second therapy into human testing later this year.
According to BioPharma Dive, the company's lead therapy is currently in Phase 1 clinical testing. The firm is developing a portfolio of small molecules aimed at inhibiting AKT, which plays a central role in the PI3K pathway—a frequently dysregulated signaling network in many tumor types. The approach seeks to overcome limitations of earlier AKT inhibitors, which struggled with toxicity and efficacy challenges.
The funding will support the progression of its lead candidate through early-stage trials and enable the advancement of a second drug candidate into clinical studies. Terremoto expects that second program to enter the clinic later this year, though specific timelines for regulatory filings or later-phase trials were not disclosed in the source material.
This substantial financing round signals investor confidence in Terremoto's approach to targeting a historically difficult cancer pathway. The AKT protein has been a focus of oncology research for years, but developing effective and safe inhibitors has proven challenging. The fresh capital provides the firm with runway to generate clinical proof-of-concept data that could validate its platform and attract potential partnership interest.
If successful, Terremoto's therapies could offer new treatment options for patients with cancers driven by AKT pathway activation. However, the field remains competitive, with several other companies also pursuing next-generation AKT inhibitors, and the clinical efficacy of the approach still needs to be demonstrated in patients.